Evonetix is a synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis.
Evonetix's technology enables the parallel synthesis of DNA on silicon arrays, to facilitate the fast-emerging field of synthetic biology, where there is increasing demand for high-throughput and highly accurate DNA synthesis.
Evonetix was founded in 2015 and is headquartered in Cambridge, Cambridgeshire, United Kingdom.
Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale.
Evonetix's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used – a new paradigm for gene synthesis. Its technology is based on a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of up to 10,000 miniaturised reaction sites.
Evonetix's technology utilises a silicon chip, made by microelectromechanical systems (MEMS) processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion.
Evonetix is backed by Draper Esprit, DCVC (Data Collective), Foresite Capital, the Morningside group, Providence Investment Company and others. The compay raised $30M (£23) in a Series B round on Mar 02, 2020. This brings Evonetix's total funding to $46M to date.